Research ExplorerPublicationsLong-term follow-up of subcutaneous versus intravenous borte...

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Standard

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. / Salwender, Hans; Elmaagacli, Ahmet; Merz, Maximilian; Miah, Kaya; Benner, Axel; Haenel, Mathias; Jehn, Christian; Mai, Elias K; Bertsch, Uta; Blau, Igor W; Scheid, Christof; Hose, Dirk; Seckinger, Anja; Jauch, Anna; Raab, Marc S; Luntz, Steffen P; Besemer, Britta; Munder, Markus; Brossart, Peter; Fuhrmann, Stephan; Lindemann, Hans-Walter; Weisel, Katja; Duerig, Jan; Goldschmidt, Hartmut.

In: LEUKEMIA, Vol. 35, No. 10, 10.2021, p. 3007-3011.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Salwender, H, Elmaagacli, A, Merz, M, Miah, K, Benner, A, Haenel, M, Jehn, C, Mai, EK, Bertsch, U, Blau, IW, Scheid, C, Hose, D, Seckinger, A, Jauch, A, Raab, MS, Luntz, SP, Besemer, B, Munder, M, Brossart, P, Fuhrmann, S, Lindemann, H-W, Weisel, K, Duerig, J & Goldschmidt, H 2021, 'Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial', LEUKEMIA, vol. 35, no. 10, pp. 3007-3011. https://doi.org/10.1038/s41375-021-01298-y

APA

Salwender, H., Elmaagacli, A., Merz, M., Miah, K., Benner, A., Haenel, M., Jehn, C., Mai, E. K., Bertsch, U., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Raab, M. S., Luntz, S. P., Besemer, B., Munder, M., Brossart, P., ... Goldschmidt, H. (2021). Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. LEUKEMIA, 35(10), 3007-3011. https://doi.org/10.1038/s41375-021-01298-y

Vancouver

Salwender H, Elmaagacli A, Merz M, Miah K, Benner A, Haenel M et al. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. LEUKEMIA. 2021 Oct;35(10):3007-3011. https://doi.org/10.1038/s41375-021-01298-y

Bibtex

@article{a446ed9e94534034aa617911aa518f6e,
title = "Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial",
author = "Hans Salwender and Ahmet Elmaagacli and Maximilian Merz and Kaya Miah and Axel Benner and Mathias Haenel and Christian Jehn and Mai, {Elias K} and Uta Bertsch and Blau, {Igor W} and Christof Scheid and Dirk Hose and Anja Seckinger and Anna Jauch and Raab, {Marc S} and Luntz, {Steffen P} and Britta Besemer and Markus Munder and Peter Brossart and Stephan Fuhrmann and Hans-Walter Lindemann and Katja Weisel and Jan Duerig and Hartmut Goldschmidt",
year = "2021",
month = oct,
doi = "10.1038/s41375-021-01298-y",
language = "English",
volume = "35",
pages = "3007--3011",
journal = "LEUKEMIA",
issn = "0887-6924",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

AU - Salwender, Hans

AU - Elmaagacli, Ahmet

AU - Merz, Maximilian

AU - Miah, Kaya

AU - Benner, Axel

AU - Haenel, Mathias

AU - Jehn, Christian

AU - Mai, Elias K

AU - Bertsch, Uta

AU - Blau, Igor W

AU - Scheid, Christof

AU - Hose, Dirk

AU - Seckinger, Anja

AU - Jauch, Anna

AU - Raab, Marc S

AU - Luntz, Steffen P

AU - Besemer, Britta

AU - Munder, Markus

AU - Brossart, Peter

AU - Fuhrmann, Stephan

AU - Lindemann, Hans-Walter

AU - Weisel, Katja

AU - Duerig, Jan

AU - Goldschmidt, Hartmut

PY - 2021/10

Y1 - 2021/10

U2 - 10.1038/s41375-021-01298-y

DO - 10.1038/s41375-021-01298-y

M3 - Other (editorial matter etc.)

C2 - 34031532

VL - 35

SP - 3007

EP - 3011

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 10

ER -